Bookmark and Share
BioAssay: AID 2345

Specificity screen against Kir2.1 for compounds that potentiate KCNQ2

Assay Implementation: Haibo Yu Ph.D., Meng Wu Ph.D., Shunyou Long M.S., Amy Scott, Beiyan Zou Ph.D., Joseph Babcock, Bill Shi Ph.D., David Meyers Ph.D., Jia Xu Ph.D. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1189)
 
 
Active(18)
 
 
Inactive(1171)
 
 
 Tested Substances
 Tested Substances
All(1189)
 
 
Active(18)
 
 
Inactive(1171)
 
 
AID: 2345
Data Source: Johns Hopkins Ion Channel Center (JHICC_KCNQ2_pot_counter_Kir2.1)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2010-02-11

Data Table ( Complete ):           View Active Data    View All Data
Target
Sequence: potassium inwardly-rectifying channel J2 [Mus musculus]
Description ..   
Protein Family: Inward rectifier potassium channel

Gene:KCNJ2     Related Protein 3D Structures     More BioActivity Data..
BioActive Compounds: 18
Related Experiments
Show more
AIDNameTypeProbeComment
1843Summary of probe development for inhibitors/blockers of inward-rectifying potassium ion channel Kir2.1Summary3 depositor-specified cross reference
2239Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channelsScreening depositor-specified cross reference: Primary HTS assay of potentiators for KCNQ2 potassium channel with 305606 compounds, of which 1644 a
2258Summary of probe development for potentiators of KCNQ2 potassium channelsSummary depositor-specified cross reference: Summary assay of KCNQ2 potentiators.
1672Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Screening same project related to Summary assay
2032Confirmatory screen for compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Screening same project related to Summary assay
2105Counter screen for compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Screening same project related to Summary assay
2236hERG counter screen for compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Screening same project related to Summary assay
2329KCNK9 specificity screen for compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Screening same project related to Summary assay
2404Manual electrophysiological patch clamp assay and ROMK specificity of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Confirmatory same project related to Summary assay
2581Automated electrophysiology assay of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Confirmatory same project related to Summary assay
2591Manual electrophysiological patch clamp assay for SAR compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Confirmatory same project related to Summary assay
2594Confirmation dose response assay for compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Confirmatory same project related to Summary assay
463252Secondary automated electrophysiology assay of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1Other same project related to Summary assay
504555Dose response assay on hERG potassium channel for Kir2.1 inhibitors on automated electrophysiologyConfirmatory same project related to Summary assay
504557Confirmation dose response assay for SAR compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1.Confirmatory same project related to Summary assay
504559Dose response assay for compounds that inhibit inward-rectifying potassium channel Kir2.1 on automated electrophysiologyConfirmatory same project related to Summary assay
504693Dose response assay on hERG potassium channel for Kir2.1 inhibitors on automated electrophysiology (II)Confirmatory same project related to Summary assay
504694Dose response assay for compounds that inhibit inward-rectifying potassium channel Kir2.1 on automated electrophysiology (II)Confirmatory same project related to Summary assay
504695Confirmation dose response assay for SAR compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1 (II)Confirmatory same project related to Summary assay
504828Manual electrophysiological patch clamp assay for extended SAR compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1_1Confirmatory same project related to Summary assay
2282Counter screen for compounds that potentiate KCNQ2 potassium channelsScreening same project related to Summary assay
2283Specificity screen against KCNQ1 for compounds that potentiate KCNQ2 potassium channelsScreening same project related to Summary assay
2287Confirmatory screen for compounds that potentiate KCNQ2 potassium channelsScreening same project related to Summary assay
2408Mode of action - current amplitude concentration response for ztz240, a potentiator of KCNQ2 potassium channelsConfirmatory same project related to Summary assay
2415Mode of Action - subtype specificity assay for ztz240, a potentiator of KCNQ2 potassium channelsScreening same project related to Summary assay
2432Mode of action assay - molecular determinants for ztz240, a potentiator of KCNQ2 potassium channelsScreening same project related to Summary assay
2443Mode of action - deactivation constant concentration response for ztz240, a potentiator of KCNQ2 potassium channelsConfirmatory same project related to Summary assay
2548Mode of action assay - current amplitude concentration response for derivatives of ZTZ240, a potentiator of KCNQ2 potassium channelsConfirmatory same project related to Summary assay
2558Mode of action - Automated patch clamp assay for KCNQ2 potentiators on Retigabine insensitive KCNQ2 Mutant W236L cell lineScreening same project related to Summary assay
2603Mode of action assay-Automated electrophysiology assay of compounds that potentiate KCNQ2 potassium channelConfirmatory same project related to Summary assay
2654Dose response of Retigabine-insensitive compounds that potentiate KCNQ2 potassium channelConfirmatory same project related to Summary assay
493037Mode of action assay-Confirmatory dose response assay for compounds that activate KCNQ2 potassium channelsConfirmatory same project related to Summary assay
493038Mode of action assay-Dose response assay for compounds that activate KCNQ2 potassium channels on automated patch clampConfirmatory same project related to Summary assay
493039Mode of action assay-Dose response assay for KCNQ2 activators in the KCNQ2/KCNQ3 co-expressing cells on automated patch clampConfirmatory same project related to Summary assay
493042Mode of action assay-Dose response assay for the identification of selective activators of KCNQ2 potassium channels in the KCNQ1/KCNE1 expressing cells on automated patch clampConfirmatory same project related to Summary assay
493043Mode of action assay-Dose response assay for the identification of selective activators of KCNQ2 potassium channels in the KCNQ4 expressing cells on automated patch clampConfirmatory same project related to Summary assay
493044Mode of action assay-Dose response assay for the identification of selective activators of KCNQ2 potassium channels in the KCNQ1 expressing cells on automated patch clampConfirmatory same project related to Summary assay
493046Mode of action assay-Specificity test for the KCNQ2 activators in the KCNQ5 expressing cellsConfirmatory same project related to Summary assay
493047Mode of action assay-Specificity test for the KCNQ2 activators in the KCNQ3 expressing cellsConfirmatory same project related to Summary assay
493113Mode of action assay-SAR analysis for compounds that activate KCNQ2 potassium channels on automated patch clampConfirmatory same project related to Summary assay
504416Mode of action assay- Specificity dose response assay for the KCNQ2 activators in the KCNQ4 expressing cells by the Tl fluxConfirmatory same project related to Summary assay
504417Mode of action assay-Specificity dose response assay for the KCNQ2 activators in the KCNQ1 expressing cells by the Tl flux assayConfirmatory same project related to Summary assay
504418Mode of action assay-Specificity dose response assay for the KCNQ2 activators in the KCNQ1/E1 expressing cells by the Tl fluxConfirmatory same project related to Summary assay
Description:
Data Source: Johns Hopkins Ion Channel Center
BioAssay Type: Specificity Screening, Single Concentration Activity Observed

Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)
Center Affiliation: Johns Hopkins University, School of Medicine
Screening Center PI: Min Li, Ph.D.
Assay Provider: Min Li, Ph.D.
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R03 DA027716-01
Grant Proposal PI: Min Li, Ph.D., Johns Hopkins University School of Medicine
Assay Implementation: Haibo Yu Ph.D., Meng Wu Ph.D., Shunyou Long M.S., Amy Scott, Beiyan Zou Ph.D., Joseph Babcock, Bill Shi Ph.D., David Meyers Ph.D., Jia Xu Ph.D.

Name: Specificity screen against KIR2.1 for compounds that potentiate KCNQ2 potassium channels

Description:
See the related primary assay (PubChem AID: 2239).
Protocol
Protocol
Assay overview:
The purpose of this assay is to assess compounds identified as active in primary screen assay (PubChem AID 2239) for their non-specific effects on Kir2.1 potassium channel. This assay employs the same experimental conditions as presented in the primary screen assay. Compounds were tested in duplicates and their effects were evaluated by the calculated fluorescence ratio percentage, normalized with negative control. If the compound causes 3SD (of negative controls) or more activity increase (from mean of negative controls) in both duplicates, the compound is considered to be active and might have non-specific effects on the Kir2.1 stably expressed HEK293 cells, which suggests that the compound is NOT specific to KCNQ2 potassium channels.
Protocol for the Kir2.1 specificity screen of KCNQ2 hits:
1. Cell culture: Cells are routinely cultured in DMEM/F12 medium, supplemented with 10% Fetal Bovine Serum (FBS), 50 IU/ml penicillin, 50ug/ml streptomycin, and 500ug/ml G418.
2. Cell plating: Add 50 ul/well of 300,000 cells/ml re-suspended in DMEM/F12 medium with 10% FBS
3. Incubate overnight at 37C and 5% CO2
4. Remove medium and add 25 ul/well of 1x FluxOR solution to cells
5. Incubate 90 minutes, at room temperature (RT), in the dark
6. Prepare 7.5X compound plates and control plates on Cybi-Well system: test compounds are prepared using assay buffer; controls are assay buffer (IC0), and IC100 of Chlorpromaizne (all with DMSO concentrations matched to that of test compounds)
7. Remove FluxOR dye solution and add 20 ul/well of assay buffer to cells
8. Add 4 ul of 7.5x compound stock into the cell plates via Cybi-Well system
9. Incubate all cell plates for 20 minutes at RT in the dark
10. Prepare 5x stimulus buffer containing 25 mM K2SO4 and 7 mM Tl2SO4
11. Load cell plates to Hamamatsu FDSS 6000 kinetic imaging plate reader.
12. Measure fluorescence for 10 seconds at 1Hz to establish baseline.
13. Depolarize cells with 6 ul/well of stimulus buffer and continue measuring fluorescence for 110 seconds.
14. Calculate ratio readout as F(max-min)/F0.
15. Calculate the average and standard deviation for negative and positive controls in each plate, as well as Z and Z'.
16. Calculate the percentage of tested compounds with the following formula:
Percentage (%)=100* (Ratio(cmpd)- AvgRatio(NC)-3*STDEVRatio(NC))/(AvgRatio(NC)-AvgRatio(Blank))
Where:
Percentage(%): percentage change of compound readout over those of negative controls (vehicle control) and 3 times of its standard deviation.
Ratio(cmpd): Ratio of the test compound.
AvgRatio(NC): Ratio average of the negative controls with stimulus buffer.
STDEVRatio(NC): Standard deviation of ratio of negative controls
Ratio(Blank): Ratio of the blank control without stimulus buffer.
17. Outcome assignment:
If the compound causes 3SD (of negative controls) or more Percentage (%) increase (from mean of negative controls) in both duplicates, the compound is labeled active as a nonspecific modulator (Value=2) in the Outcome. Otherwise, it is designated as inactive (Value=1).
18. Score assignment
An inactive test compound is assigned the score of 0.
An active test compound is assigned a score between 0 and 100 by calculation of INT(Percentage(%)).
Percentage(%) is the averaged percentage of the duplicates of the test compound over the 3SD of negative controls normalized to the smallest (0%) and the largest (100%) values.
List of reagents
1. Kir2.1-HEK293 cell lines (provided by JHICC)
2. PBS: pH7.4 (Gibco, Cat#10010)
3. Medium: DMEM/F12 50/50 (Mediatech, Cat#15-090-CV)
4. Fetal Bovine Serum (Gemini, Cat# 100-106)
5. 200 mM L-Glutamine (Gibco, Cat#25030)
6. 100x Penicillin-Streptomycin (Mediatech, Cat#30-001-CI)
7. 0.05% Trypsin-EDTA (Gibco, Cat#25300)
8. Geneticin: (Gibco, Cat#11811-031)
9. HEPES (Sigma, Cat#H4034)
10. Chlorpromazine hydrochloride (Sigma, C8138)
11.FluxOR detection kit (Invitrogen, Cat #F10017): FluxOR, assay buffer and stimulus buffer.
12. Triple-layer flask (VWR, Cat #62407-082)
13. BD Biocoat 384-well plates (BD, Cat# (35)4663 and Lot #7346273)
Comment
Possible artifacts of this assay may include, but are not limited to: unintended chemicals or dust in or under the wells of the microtiter plate, or compounds that quench or emit light or fluorescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR. Normalization is to this set of data and cannot be used for comparison with other screens.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Percentage (10μM**)Percentage of the test compound readout over the 3SD of negative controls at a concentration of 10 uM.Float

** Test Concentration.
Additional Information
Grant Number: 1 R03 DA027716-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: